122 related articles for article (PubMed ID: 30431391)
1. Comparative study of the binding mode between cytochrome P450 17A1 and prostate cancer drugs in the absence of haem iron.
Song D; Zhang J; Wang Y; Hu J; Xu S; Xu Y; Shen H; Wen X; Sun Z
J Biomol Struct Dyn; 2019 Oct; 37(16):4161-4170. PubMed ID: 30431391
[TBL] [Abstract][Full Text] [Related]
2. Structures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
DeVore NM; Scott EE
Nature; 2012 Jan; 482(7383):116-9. PubMed ID: 22266943
[TBL] [Abstract][Full Text] [Related]
3. Comparisons of Prostate Cancer Inhibitors Abiraterone and TOK-001 Binding with CYP17A1 through Molecular Dynamics.
Xiao F; Yang M; Xu Y; Vongsangnak W
Comput Struct Biotechnol J; 2015; 13():520-7. PubMed ID: 26682016
[TBL] [Abstract][Full Text] [Related]
4. Structural and Functional Evaluation of Clinically Relevant Inhibitors of Steroidogenic Cytochrome P450 17A1.
Petrunak EM; Rogers SA; Aubé J; Scott EE
Drug Metab Dispos; 2017 Jun; 45(6):635-645. PubMed ID: 28373265
[TBL] [Abstract][Full Text] [Related]
5. Human cytochrome P450 17A1 structures with metabolites of prostate cancer drug abiraterone reveal substrate-binding plasticity and a second binding site.
Petrunak EM; Bart AG; Peng HM; Auchus RJ; Scott EE
J Biol Chem; 2023 Mar; 299(3):102999. PubMed ID: 36773804
[TBL] [Abstract][Full Text] [Related]
6. New steroidal oxazolines, benzoxazoles and benzimidazoles related to abiraterone and galeterone.
Latysheva AS; Zolottsev VA; Veselovsky AV; Scherbakov KA; Morozevich GE; Pokrovsky VS; Novikov RA; Timofeev VP; Tkachev YV; Misharin AY
Steroids; 2020 Jan; 153():108534. PubMed ID: 31678134
[TBL] [Abstract][Full Text] [Related]
7. Interaction of 17α-hydroxylase, 17(20)-lyase (CYP17A1) inhibitors - abiraterone and galeterone - with human sterol 14α-demethylase (CYP51A1).
Masamrekh R; Kuzikov A; Veselovsky A; Toropygin I; Shkel T; Strushkevich N; Gilep A; Usanov S; Archakov A; Shumyantseva V
J Inorg Biochem; 2018 Sep; 186():24-33. PubMed ID: 29807244
[TBL] [Abstract][Full Text] [Related]
8. Structure-Based Design of Inhibitors with Improved Selectivity for Steroidogenic Cytochrome P450 17A1 over Cytochrome P450 21A2.
Fehl C; Vogt CD; Yadav R; Li K; Scott EE; Aubé J
J Med Chem; 2018 Jun; 61(11):4946-4960. PubMed ID: 29792703
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.
Bruno RD; Vasaitis TS; Gediya LK; Purushottamachar P; Godbole AM; Ates-Alagoz Z; Brodie AM; Njar VC
Steroids; 2011 Nov; 76(12):1268-79. PubMed ID: 21729712
[TBL] [Abstract][Full Text] [Related]
10. Promising Tools in Prostate Cancer Research: Selective Non-Steroidal Cytochrome P450 17A1 Inhibitors.
Bonomo S; Hansen CH; Petrunak EM; Scott EE; Styrishave B; Jørgensen FS; Olsen L
Sci Rep; 2016 Jul; 6():29468. PubMed ID: 27406023
[TBL] [Abstract][Full Text] [Related]
11. CYP17A1 inhibitor abiraterone, an anti-prostate cancer drug, also inhibits the 21-hydroxylase activity of CYP21A2.
Malikova J; Brixius-Anderko S; Udhane SS; Parween S; Dick B; Bernhardt R; Pandey AV
J Steroid Biochem Mol Biol; 2017 Nov; 174():192-200. PubMed ID: 28893623
[TBL] [Abstract][Full Text] [Related]
12. Slow-, Tight-Binding Inhibition of CYP17A1 by Abiraterone Redefines Its Kinetic Selectivity and Dosing Regimen.
Cheong EJY; Nair PC; Neo RWY; Tu HT; Lin F; Chiong E; Esuvaranathan K; Fan H; Szmulewitz RZ; Peer CJ; Figg WD; Chai CLL; Miners JO; Chan ECY
J Pharmacol Exp Ther; 2020 Sep; 374(3):438-451. PubMed ID: 32554434
[TBL] [Abstract][Full Text] [Related]
13. Direct regulation of androgen receptor activity by potent CYP17 inhibitors in prostate cancer cells.
Soifer HS; Souleimanian N; Wu S; Voskresenskiy AM; Collak FK; Cinar B; Stein CA
J Biol Chem; 2012 Feb; 287(6):3777-87. PubMed ID: 22174412
[TBL] [Abstract][Full Text] [Related]
14. Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate Cancer.
Bordeau BM; Ciulla DA; Callahan BP
ChemMedChem; 2016 Sep; 11(18):1983-6. PubMed ID: 27435344
[TBL] [Abstract][Full Text] [Related]
15. Illuminating cytochrome P450 binding: Ru(ii)-caged inhibitors of CYP17A1.
Li A; Yadav R; White JK; Herroon MK; Callahan BP; Podgorski I; Turro C; Scott EE; Kodanko JJ
Chem Commun (Camb); 2017 Mar; 53(26):3673-3676. PubMed ID: 28304025
[TBL] [Abstract][Full Text] [Related]
16. Stepwise binding of inhibitors to human cytochrome P450 17A1 and rapid kinetics of inhibition of androgen biosynthesis.
Guengerich FP; McCarty KD; Chapman JG; Tateishi Y
J Biol Chem; 2021 Aug; 297(2):100969. PubMed ID: 34273352
[TBL] [Abstract][Full Text] [Related]
17. Pregnenolonyl-α-glucoside exhibits marked anti-cancer and CYP17A1 enzymatic inhibitory activities.
Chou FP; Hsu WC; Huang SC; Chang CY; Chiou YS; Tsai CT; Lyu JW; Chen WT; Wu TK
Chem Commun (Camb); 2020 Feb; 56(11):1733-1736. PubMed ID: 31938799
[TBL] [Abstract][Full Text] [Related]
18. The hunt for a selective 17,20 lyase inhibitor; learning lessons from nature.
Bird IM; Abbott DH
J Steroid Biochem Mol Biol; 2016 Oct; 163():136-46. PubMed ID: 27154414
[TBL] [Abstract][Full Text] [Related]
19. Novel oxazolinyl derivatives of pregna-5,17(20)-diene as 17α-hydroxylase/17,20-lyase (CYP17A1) inhibitors.
Kuzikov AV; Dugin NO; Stulov SV; Shcherbinin DS; Zharkova MS; Tkachev YV; Timofeev VP; Veselovsky AV; Shumyantseva VV; Misharin AY
Steroids; 2014 Oct; 88():66-71. PubMed ID: 24971814
[TBL] [Abstract][Full Text] [Related]
20. Structural and kinetic basis of steroid 17α,20-lyase activity in teleost fish cytochrome P450 17A1 and its absence in cytochrome P450 17A2.
Pallan PS; Nagy LD; Lei L; Gonzalez E; Kramlinger VM; Azumaya CM; Wawrzak Z; Waterman MR; Guengerich FP; Egli M
J Biol Chem; 2015 Feb; 290(6):3248-68. PubMed ID: 25533464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]